Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 48, Issue 6, Pages 1729-1744Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm0497949
Keywords
-
Categories
Ask authors/readers for more resources
Modification of a series of pyrazole factor Xa inhibitors to incorporate an aminobenzisoxazole as the P, ligand resulted in compounds with improved selectivity for factor Xa relative to trypsin and plasma kallikrein. Further optimization of the P-4 moiety led to compounds with enhanced permeability and reduced protein binding. The SAR and pharmacokinetic profile of this series of compounds is described herein. These efforts culminated in 1-(3 '-aminobenzisoxazol-5 '-yl)3-trifluoromethyl-N-[2-fluoro-4-[(2 '-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole- 5-carboxyamide (11d), a potent, selective, and orally bioavailable inhibitor of factor Xa. On the basis of its excellent in vitro potency and selectivity profile, high free fraction in human plasma, good oral bioavailability, and in vivo efficacy in antithrombotic models, the HCl salt of this compound was selected for clinical development as razaxaban (DPC 906, BMS-561389).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available